A Phase 1 interventional study of Placebo and Linagliptin in Diabetes Mellitus, Type 2, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-01-19.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 67 studies testing linagliptin in Diabetes Mellitus, Type 2 — 1 open to participants now, 1 under way, none of them phase 3. Linagliptin · Diabetes Mellitus, Type 2.
Among the 67 studies testing linagliptin in Diabetes Mellitus, Type 2, this one is the 51st largest by enrollment, is one of 6 that started in 2012, is one of 7 in phase 1, and was the 30th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →1 of the 67 studies testing linagliptin in Diabetes Mellitus, Type 2 is open now, in 1 country. Recruiting first, the newest first:
Bahria University · Sites in Pakistan
Ages 30–55
By country, each count listing its studies:
Linagliptin: first FDA approval 2011 (TRADJENTA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
67 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 6 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 42 is below the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 175 across the 67 interventional studies. Of the 60 that completed or were terminated, 41 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
42 of 67 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim: 2 open now, 3 under way, 2 of them phase 3. Of 125 finished, 109 (87%) have results posted.
Among the 130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim, this one is the 84th largest by enrollment of the 96 interventional ones that give a count, is one of 9 that started in 2012, is one of 19 in phase 1, and was the 63rd registered.
Boehringer Ingelheim’s Diabetes Mellitus, Type 2 studies by the year they started, since 1997.
None of the studies under way reaches primary completion within a year.
Among the 67 studies testing linagliptin in Diabetes Mellitus, Type 2, from their registry updates:
Among Boehringer Ingelheim’s 130 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
The general aim of the present study is to investigate the impact of 4 weeks treatment with linagliptin (5 mg) on endothelial function in patients with type 2 diabetes mellitus. In the current trial this effect of linagliptin treatment on endothelial function will be compared against both the sulfonylurea glimepiride and against placebo, which has not been tested in a trial before; as also is the case for other DPP-4 inhibitors.
Besides placebo, glimepiride was chosen as a comparator, as it is one compound of the second most used oral antidiabetic drug class.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Type 2 diabetic male and female patients according to the following criteria:
Based upon a complete medical history and clinical laboratory tests
Signed and dated written prior to admission to the study in accordance with GCP and the local legislation.
For female patients of :
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
given once daily over 28 days
Drug: Placebo · Drug: Linagliptin
given once daily in 1mg dosis over 7 days, following a titration step to 2mg and application for 21 days
Drug: Placebo · Drug: Glimepiride
given once daily over 28 days
Drug: Placebo
Placebo matching Glimepiride
given once daily for 28 days
Placebo matching Linagliptin
Placebo matching Linagliptin
Placebo matching Glimepiride
1 mg for 7 days followed by uptitration to 2 mg (given for following 21 days)
Change From Baseline in Flow Mediated Vasodilation (FMD) Under Fasted Condition on Day 28
Endothelial function under fasted condition was measured with flow mediated vasodilation (FMD). The change from baseline was calculated as the value on Day 28 divided by the respective value at baseline.
Time frame: baseline and day 28 for each treatment arm
Change From Baseline in Flow Mediated Vasodilation (FMD) 2 h Post Meal on Day 28
Endothelial function 2 hours post meal was measured with flow mediated vasodilation (FMD). The change from baseline was calculated as the value on Day 28 divided by the respective value at baseline.
Time frame: baseline and day 28 for each treatment arm
Change From Baseline in 2 Hours Post Meal Endothelial Independent Vasodilation (EIDV) on Day 28
Endothelial function 2h post-meal was measured by endothelial independent vasodilation (EIDV). The change from baseline was calculated as the value on Day 28 divided by the respective value at baseline.
Time frame: baseline and day 28 for each treatment arm
Number of Patients With Adverse Events
Number of patients with any adverse events
Time frame: up to 20 weeks
| Milestone | Pbo/ G1-4/ L 5 | L 5/ G 1-4/ Pbo | G 1-4/ L 5/ Pbo | G1-4/ Pbo/ L 5 | Pbo/ L 5/ G1-4 | L 5/ Pbo/ G1-4/ |
|---|---|---|---|---|---|---|
| Started | 7 | 7 | 7 | 7 | 7 | 7 |
| Completed | 7 | 7 | 7 | 6 | 7 | 6 |
| Not completed | 0 | 0 | 0 | 1 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 | 0 | 1 |
| Milestone | Pbo/ G1-4/ L 5 | L 5/ G 1-4/ Pbo | G 1-4/ L 5/ Pbo | G1-4/ Pbo/ L 5 | Pbo/ L 5/ G1-4 | L 5/ Pbo/ G1-4/ |
|---|---|---|---|---|---|---|
| Started | 7 | 7 | 7 | 6 | 7 | 6 |
| Completed | 7 | 7 | 7 | 5 | 7 | 6 |
| Not completed | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 | 0 | 0 |
| Milestone | Pbo/ G1-4/ L 5 | L 5/ G 1-4/ Pbo | G 1-4/ L 5/ Pbo | G1-4/ Pbo/ L 5 | Pbo/ L 5/ G1-4 | L 5/ Pbo/ G1-4/ |
|---|---|---|---|---|---|---|
| Started | 7 | 7 | 7 | 5 | 7 | 6 |
| Completed | 7 | 7 | 7 | 5 | 7 | 6 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
Endothelial function under fasted condition was measured with flow mediated vasodilation (FMD). The change from baseline was calculated as the value on Day 28 divided by the respective value at baseline.
| percentage | Linagliptin 5 mg | Glimepiride 1-4 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Flow Mediated Vasodilation (FMD) Under Fasted Condition on Day 28 | 0.885 (0.695 to 1.128) | 1.002 (0.795 to 1.262) | 1.002 (0.786 to 1.277) |
Endothelial function 2 hours post meal was measured with flow mediated vasodilation (FMD). The change from baseline was calculated as the value on Day 28 divided by the respective value at baseline.
| Percentage | Linagliptin 5 mg | Glimepiride 1-4 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Flow Mediated Vasodilation (FMD) 2 h Post Meal on Day 28 | 1.262 (0.968 to 1.646) | 1.045 (0.815 to 1.339) | 1.009 (0.777 to 1.311) |
Endothelial function 2h post-meal was measured by endothelial independent vasodilation (EIDV). The change from baseline was calculated as the value on Day 28 divided by the respective value at baseline.
| percentage | Linagliptin 5 mg | Glimepiride 1-4 mg | Placebo |
|---|---|---|---|
| Change From Baseline in 2 Hours Post Meal Endothelial Independent Vasodilation (EIDV) on Day 28 | 1.003 (0.945 to 1.061) | 1.053 (0.998 to 1.108) | 0.981 (0.923 to 1.039) |
Number of patients with any adverse events
| participants | Linagliptin 5 mg | Glimepiride 1-4 mg | Placebo | REP - Linagliptin 5 mg | REP - Glimepiride 1-4 mg | Rep - Placebo |
|---|---|---|---|---|---|---|
| Number of Patients With Adverse Events | 11 | 25 | 14 | 4 | 7 | 7 |
Collected over 28 days treatment period + 7 days residual effect period. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Linagliptin 5 mg | — | 0/40 (0%) | 6/40 (15%) |
| Glimepiride 1-4 mg | — | 0/41 (0%) | 20/41 (48.8%) |
| Placebo | — | 0/40 (0%) | 9/40 (22.5%) |
| Event | Linagliptin 5 mg | Glimepiride 1-4 mg | Placebo |
|---|---|---|---|
| HypoglycaemiaMetabolism and nutrition disorders | 2/40 | 16/41 | 1/40 |
| HeadacheNervous system disorders | 4/40 | 3/41 | 6/40 |
| NasopharyngitisInfections and infestations | 1/40 | 6/41 | 3/40 |
| HyperhidrosisSkin and subcutaneous tissue disorders | 0/40 | 3/41 | 0/40 |
TS (treated set) - included all patients who were dispensed trial medication and were documented to have taken at least 1 dose of trial drug.
| Age, Continuous(years) | Total Participants |
|---|---|
| Mean | 60.3 ± 6.0 |
| Sex: Female, Male(Participants) | Total Participants |
|---|---|
| Female | 14 |
| Male | 28 |
The record gives a start of Oct 2012, a primary completion of Jan 2014 and a completion of Jan 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2015, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Linagliptin